Gain Therapeutics (GANX) Competitors $1.89 -0.18 (-8.70%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.94 +0.05 (+2.65%) As of 03/28/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX vs. DRUG, LFCR, MNPR, ENGN, FHTX, YMAB, NVCT, KRRO, INMB, and TVGNShould you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Bright Minds Biosciences (DRUG), Lifecore Biomedical (LFCR), Monopar Therapeutics (MNPR), enGene (ENGN), Foghorn Therapeutics (FHTX), Y-mAbs Therapeutics (YMAB), Nuvectis Pharma (NVCT), Korro Bio (KRRO), INmune Bio (INMB), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry. Gain Therapeutics vs. Bright Minds Biosciences Lifecore Biomedical Monopar Therapeutics enGene Foghorn Therapeutics Y-mAbs Therapeutics Nuvectis Pharma Korro Bio INmune Bio Tevogen Bio Bright Minds Biosciences (NASDAQ:DRUG) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends. Do analysts rate DRUG or GANX? Bright Minds Biosciences presently has a consensus price target of $84.33, indicating a potential upside of 131.05%. Gain Therapeutics has a consensus price target of $8.20, indicating a potential upside of 333.86%. Given Gain Therapeutics' higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the MarketBeat Community prefer DRUG or GANX? Gain Therapeutics received 32 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users. However, 100.00% of users gave Bright Minds Biosciences an outperform vote while only 73.08% of users gave Gain Therapeutics an outperform vote. CompanyUnderperformOutperformBright Minds BiosciencesOutperform Votes6100.00% Underperform VotesNo VotesGain TherapeuticsOutperform Votes3873.08% Underperform Votes1426.92% Which has more risk and volatility, DRUG or GANX? Bright Minds Biosciences has a beta of -6.45, indicating that its share price is 745% less volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Is DRUG or GANX more profitable? Bright Minds Biosciences' return on equity of -5.85% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -5.85% -5.68% Gain Therapeutics N/A -203.91%-128.05% Do insiders & institutionals believe in DRUG or GANX? 40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 11.7% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor DRUG or GANX? In the previous week, Gain Therapeutics had 8 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 9 mentions for Gain Therapeutics and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.92 beat Gain Therapeutics' score of 0.98 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Overall Sentiment Bright Minds Biosciences Very Positive Gain Therapeutics Positive Which has better valuation & earnings, DRUG or GANX? Bright Minds Biosciences has higher earnings, but lower revenue than Gain Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.17-214.71Gain Therapeutics$50K1,002.65-$22.27M-$1.10-1.72 SummaryBright Minds Biosciences beats Gain Therapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GANX vs. The Competition Export to ExcelMetricGain TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.13M$6.90B$5.63B$7.83BDividend YieldN/A2.74%4.57%4.01%P/E Ratio-1.727.1723.3318.67Price / Sales1,002.65218.11387.5690.67Price / CashN/A65.6738.1634.64Price / Book1.956.396.894.23Net Income-$22.27M$142.12M$3.20B$247.15M7 Day Performance-19.23%-5.06%-2.98%-2.17%1 Month Performance-11.27%-7.49%1.63%-5.68%1 Year Performance-49.87%-10.91%9.44%-0.74% Gain Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GANXGain Therapeutics3.1913 of 5 stars$1.89-8.7%$8.20+333.9%-49.9%$50.13M$50,000.00-1.7220Earnings ReportAnalyst ForecastNews CoveragePositive NewsDRUGBright Minds Biosciences2.766 of 5 stars$34.80-1.0%$84.33+142.3%+2,941.9%$245.13MN/A-204.69N/APositive NewsLFCRLifecore Biomedical1.365 of 5 stars$6.60+0.8%$8.00+21.2%+29.0%$244.37M$130.86M-11.79690News CoverageMNPRMonopar Therapeutics1.1825 of 5 stars$37.60-6.0%$44.00+17.0%+1,084.4%$244.10MN/A-19.0910Gap UpENGNenGene3.1945 of 5 stars$4.63-6.7%$25.22+444.8%-74.6%$236.02MN/A-7.9831FHTXFoghorn Therapeutics2.6321 of 5 stars$4.22+4.2%$13.17+212.0%-47.5%$234.68M$22.60M-2.20120Positive NewsGap UpYMABY-mAbs Therapeutics3.6806 of 5 stars$5.16+3.2%$18.30+254.7%-70.4%$233.33M$87.69M-9.56150NVCTNuvectis Pharma2.6292 of 5 stars$9.81-3.8%$15.00+52.9%+27.6%$229.48MN/A-8.468KRROKorro Bio1.4889 of 5 stars$24.03+1.1%$142.57+493.3%-80.6%$225.62M$2.27M-2.5670Gap UpINMBINmune Bio1.7312 of 5 stars$8.30+2.2%$22.80+174.7%-36.0%$220.71M$42,000.00-3.8110Earnings ReportNews CoverageTVGNTevogen Bio3.1684 of 5 stars$1.24+8.8%$7.10+472.6%-68.0%$217.06MN/A0.003 Remove Ads Related Companies and Tools Related Companies Bright Minds Biosciences Alternatives Lifecore Biomedical Alternatives Monopar Therapeutics Alternatives enGene Alternatives Foghorn Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Nuvectis Pharma Alternatives Korro Bio Alternatives INmune Bio Alternatives Tevogen Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GANX) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
